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a b s t r a c t
T-cell prolymphocytic leukemia (T-PLL), a rare type of peripheral T-cell leukemia, is characterized by
marked splenomegaly with rapidly progressive lymphocytosis and a poor prognosis. Nine kinds of ABL1
chimeric genes have been identiﬁed in various kinds of hematological malignancies, such as chronic
myeloid leukemia and B- or T-lymphoblastic leukemia. However, there have been no reports describing
T-PLL cases with ABL1 rearrangements. We herein report a case of T-PLL with a novel SEPT9-ABL1 fusion
gene which induced strong resistance to tyrosine kinase inhibitors such as imatinib and dasatinib.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
T-cell prolymphocytic leukemia (T-PLL) is a rare type of
peripheral T-cell leukemia with a naive T-cell phenotype [1]. The
clinical features of T-PLL include marked hepatosplenomegaly and
generalized lymphadenopathy with rapidly progressive lympho-
cytosis. The prognosis is generally poor due to resistance to
chemotherapy, with a median survival ranging from 7.5 to 50
months [1–3]. Chromosomal abnormalities such as t(14;14)(q11;
q32), inv(14)(q11;q32) and t(X;14)(q28;q11) have been identiﬁed
in patients with T-PLL, which result in the rearrangement of the
TCL1 or MTCP1 genes with the T-cell receptor loci, which were
thought to contribute to the pathogenesis of T-PLL [3].
We herein report a case of T-PLL with a novel ABL1 fusion
gene which was fused to SEPT9, SEPT9-ABL1. The case exhibited
strong resistance to the tyrosine kinase inhibitors (TKI) used
against BCR-ABL1. This is the ﬁrst report of T-PLL with an ABL1
fusion gene, and additionally, only the second report of a
hematological malignancy with an ABL1 fusion gene that exhib-
ited a poor response to TKI.
2. Case report
A 70-year-old male was admitted to our hospital due to leuko-
cytosis. On a physical examination, lymphadenopathy extending
from the bilateral cervical to supraclavicular regions with moder-
ate hepatomegaly was noted. The laboratory data on admission
were as follows: white blood cells (WBC), 248109/L with 0%
neutrophils, 1% lymphocytes, 1% monocytes, 0% eosinophils, 0%
basophils and 98% atypical lymphocytes, which were medium-
sized with pale cytoplasm and prominent nucleoli (Fig. 1A); red
blood cells (RBC), 4110109/L; hemoglobin (Hb), 12.4 g/dl; and
platelets (Plt), 171109/L. Blood biochemistry was normal, except
for elevated levels of lactate dehydrogenase and hepatobiliary
enzymes. Bone marrow aspirate smears showed marked prolifera-
tion of atypical lymphocytes with a similar morphology to that of
the peripheral blood cells. Using a cytogenetic analysis, six of six
metaphases examined were 46, XY. A ﬂow cytometric analysis
showed that the atypical lymphocytes were positive for CD2, CD4,
CD5 and CD7. A BCR-ABL FISH analysis showed no BCR-ABL signals,
although 79 of 100 bone marrow cells exhibited atypical signals
(ABL1: three copies and BCR: two copies in each cell) (Fig. 1B). The
three ABL1 signals indicated either simple ampliﬁcation of the
ABL1 gene or the presence of ABL1 rearrangement. In order to
examine these two possibilities, the 50-terminal sequence of the
ABL1 gene was analyzed using the 50 RACE PCR method (SMARTer
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RACE cDNA Ampliﬁcation Kit, Takara Bio, Shiga, Japan), according
to the manufacturer's protocol. Sequencing of the PCR products
demonstrated the fusion of exon 4 of SEPT9 to exon 2 of ABL1
(Fig. 1C), suggesting that the SEPT9-ABL1 fusion gene had the same
breakpoint in ABL1 as that seen in BCR-ABL1. The presumed
structure of the SEPT9-ABL1 fusion product is shown in Fig. 1D.
A Western blot analysis revealed the expression and phosphoryla-
tion of SEPT9-ABL1, in addition to the phosphorylation of a
downstream target CRKL, in the T-PLL cells obtained from the
patient (Fig. 1E). Taking into account the patient's clinical, mor-
phological, immunophenotypic and molecular features, he was
diagnosed with T-PLL harboring SEPT9-ABL1. This is the ﬁrst report
of a novel SEPT9-ABL1 fusion gene in a patient with malignancy, as
well as T-PLL harboring ABL1 fusion.
The patient received multiagent chemotherapy using cyclopho-
sphamide, daunorubicin, vincristine, predonisolone and L-aspara-
ginase, and high dose MTX/Ara-C, as well as the single-agent
administration of nelarabine, hydroxyurea and tyrosine kinase
inhibitors (TKIs) (imatinib and dasatinib). The conventional che-
motherapies and cytotoxic agents effectively reduced the WBC
count, however, TKIs were unable to do so. He ﬁnally died on day
223 after diagnosis (Fig. 2A). An autopsy was performed, and a
macroscopic examination showed generalized lymphadenopathy
with an enlarged lung, liver, spleen and kidney, while a micro-
scopic examination disclosed leukemic cell inﬁltration throughout
multiple organs (Fig. 2B). These ﬁndings suggested the occurrence
of multiple organ failure due to a progression of leukemia which
eventually caused the patient's death.
3. Discussion
ABL1 is a well-known oncogene that is often associated with
the formation of fusion genes, such as BCR-ABL1, in human
leukemia. The wild-type ABL1 product transduces diverse extra-
cellular signals to protein networks that control proliferation,
survival, migration and invasion [4]. Additionally, ABL1 modulates
development and cytoskeletal remodeling processes in T-cells.
To date, nine genes, including BCR, have been shown to fuse to
ABL1 [5]. These genes are divided into two groups according to
their structure: one group has a breakpoint in exon 2 including the
Src Homology (SH) 2 and SH3 domains in the fusion products and
is found in various kinds of leukemia, while the other has a
breakpoint in exon 4 excluding these domains and is primarily
found in patients with B-lymphoblastic leukemia (B-ALL). Both
groups share the C-terminus structure, including the SH1 tyrosine
kinase domain. The N-terminal of the fusion proteins usually
includes a coiled-coil or helix-loop-helix domain from the partner
protein, which induces the oligomerization of the proteins, thus
resulting in tyrosine kinase activation, cytoskeletal localization
and neoplastic transformation [5].
Fig. 1. Clinical and molecular characteristics of T-PLL harboring the SEPT9-ABL1 fusion gene. (A) Cytology of the leukemic cells in the peripheral blood at diagnosis. The smear
underwent Wright–Giemsa staining. (B) A FISH analysis of the bone marrow cells using the BCR-ABL1 probe. The red signals show three ABL1 signals, including one normal
and two split signals (indicated by the lower arrows), while the green signals show normal biallelic BCR signals (indicated by the upper arrows). No BCR-ABL1 fusion signals
were detected. (C) Identiﬁcation of SEPT9-ABL1 fusion in the T-PLL cells. The PCR products of 5' RACE PCR using the ABL1 reverse primer were cloned into a cloning vector.
Sequencing of the PCR products showed a fusion of exon 4 of SEPT9 transcript variant 1 (GenBank accession number: NM_001113491.1) to exon 2 of ABL1 transcript variant a
(GenBank accession number: NM_005157.4). (D) The presumed structure of the SEPT9-ABL1 fusion product. (E) The phosphorylation of SEPT9-ABL1 and the downstream
target CRKL in the T-PLL cells obtained from the patient. K562 cells and T-cells derived from a healthy donor were used as positive and negative controls for ABL1 fusion.
Anti-ABL1 and anti-phosphorylated-ABL1 antibodies detected three SEPT9-ABL1 bands corresponding to 180, 170 and 150 KDa in the patient (arrowheads), as well as
210 KDa BCR-ABL1 in the K562 cells (asterisks), demonstrating the expression and phosphorylation of SEPT9-ABL1. CRKL was phosphorylated only in the cells harboring
ABL1 fusion. The anti-phospho-Abl (Tyr412), anti-Abl, anti-phospho-Crkl (Tyr207) and anti-Crkl antibodies were purchased from Cell Signaling, and anti-β-actin was
purchased from Sigma-Aldrich.
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Septin proteins belong to a family of proteins that is highly
conserved in eukaryotes [6]. These proteins are GTP-binding
proteins that form hetero-oligomeric complexes. There are 13
septin genes in humans [6]. The SEPT9 gene exists at chromosomal
location 17q25 and exhibits a ubiquitous expression. SEPT9 plays a
role in many cellular mechanisms, such as actin dynamics, axon
growth, determination of the cell shape, chromosome segregation,
cytokinesis, dendrite formation, DNA repair, membrane trafﬁcking,
microtubule regulation and T-cell motility [6]. Furthermore, SEPT9
is deeply associated with the development of various cancers
(breast, colon, head, ovarian, neck, leukemia, lymphoma) [6].
In particular, it has been shown that SEPT9 is a putative proto-
oncogene involved in T-cell lymphomagenesis in mice [7].
In patients with hematological malignancies,MLL (KMT2A)-septin
fusion has been repeatedly identiﬁed in cells exhibiting myeloid
neoplasia in both children and adults. Five different septin genes
(SEPT2, SEPT5, SEPT6, SEPT9 and SEPT11) have been identiﬁed to be
MLL fusion partners [8]. The C-terminal coiled-coil region of septin
proteins is preserved in all MLL-septin fusion products, thus indicat-
ing that this region contributes to protein–protein interactions and
ultimately oncogenesis. In contrast, the N-terminal of SEPT9 is fused
to ABL1 in the SEPT9-ABL1 fusion product. It includes the Pro-rich
region, which is necessary for binding with SH 3 regions [9]. Because
the SH3 domain of ABL1 is preserved in SEPT9-ABL1, this Pro-rich
region may contribute to an enhanced chimeric ABL1 kinase poten-
tial by promoting interaction with ABL1 SH3 regions, thereby
synergistically inducing leukemogenesis.
Regarding the effectiveness of TKIs, some, but not all, patients
carrying the NUP214-ABL1 or ETV6-ABL1 fusion gene respond to
such therapy [5]. A recent report showed that B-ALL with SNX2-
ABL1 responds poorly to dasatinib but partially to imatinib [10,11].
In the present case, SEPT9-ABL1 exhibited a strong resistance to
both imatinib and dasatinib. We conﬁrmed that there were no
point mutations in the SEPT9-ABL1 fusion gene. These ﬁndings
indicate that the TKI response in patients with hematological
malignancies associated with various ABL1 fusion products is
dependent on the ABL1-partner genes. Further examinations,
including conformational analyses of ABL1 fusion products, such
as SEPT9-ABL1, and genetic alteration screening of ABL1 fusion-
expressing cells, will provide clues uncovering the mechanisms for
determining sensitivity to TKI therapy in patients with hematolo-
gical malignancies harboring ABL1 fusion products.
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